Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Executive Moves at Gilead | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Executive Moves at Gilead

Dr. Cheng and Dr. Yang join the senior leadership committee

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Andrew Cheng, MD, Ph.D., has been appointed executive vice president, HIV Therapeutics and Development Operations at Gilead Sciences, and Taiyin Yang, Ph.D., has been appointed executive vice president, Pharmaceutical Development and Manufacturing. Both Dr. Cheng and Dr. Yang will join the senior leadership committee.
 
Dr. Cheng joined the company in 1999 and has led clinical development activities for development-stage programs in HIV/AIDS. In 2009, he was appointed senior vice president, HIV Therapeutics and Development Operations, assuming additional responsibility for biometrics, clinical operations, clinical pharmacology, drug safety and public health, project management and regulatory affairs. Dr. Cheng reports to Norbert Bischofberger, Ph.D., executive vice president, R&D and chief scientific officer.  
 
Dr. Yang joined the company in 1993 and was promoted to senior vice president in 2005. In her role, Dr. Yang is responsible for managing pharmaceutical development, analytical operations, lab information, quality assurance and manufacturing of both clinical and commercial drug substance and drug product. She reports to Dr. Bischofberger and to John Milligan, Ph.D., president and chief operating officer. Prior to joining the company, Dr. Yang was director of Analytical Chemistry at Syntex.  
 
“Andrew and Taiyin have both demonstrated leadership in bringing groups together to help expedite the development and manufacturing of products – ultimately allowing the company to reach patients in need more quickly,” commented Dr. Bischofberger. “They are experts in their respective fields and have helped build teams that are efficient and highly productive. These promotions recognize their achievements and dedication to bringing innovative new therapies to patients around the world.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics